COMP <GO>
RVMD vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Revolution Medicines Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RVMD 3
— JNJ 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RVMD
LAST: $191.31 (+0.55%) • MKT CAP: $40.78B
balance-sheet
26.00
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 67.90% | -23.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.60% | 25.50% | -54.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | 2.97% | -5.21 | JNJ | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.70% | -18.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.50% | -16.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 6.00% | +9.40 | RVMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.59 | +20.41 | RVMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | RVMD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 60.4 | -11.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 23.0x | +11.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.78B | $662.49B | -$621.71B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVMD REV | JNJ REV | RVMD GROSS % | JNJ GROSS % | RVMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$913.7M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$567.7M | $19.84B |
| FY 2023 | $11.6M | $85.16B | 44.0% | 44.0% | -$351.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVMD // BETA 1.07
JNJ // BETA 1.08